BioNexus Gene Lab Corp. BGLC
Regular-session close
After hours · Nov 19, 4:00 PM ET
- YTD
- -82.78%
- 1 year
- -85.80%
- Market cap
- 1.99M
- Revenue (ttm)
- 9.18M
- Profit margin
- -24.01%
- EPS (ttm)
- -1.26
- Shares out
- 17.97M
- YTD return
- -82.78%
- 1-year return
- -85.80%
- Volume
- 10.44K
- Avg volume
- 6.55K
- Open
- 0.753
- Previous close
- 0.7335
- Day's range
- 0.6586 – 0.753
- 52-week range
- 0.6586 – 4.97
- Beta
- 1.87
Key statistics
- 50-day average
- 0.31938
- 200-day average
- 0.470585
- Enterprise value
- 427.71K
- Price / sales
- 0.48
- Price / book
- 0.44
- Revenue growth
- -23.10%
- Free cash flow
- -190.55K
- Total cash
- 5.41M
- Total debt
- 451.45K
- Return on equity
- -28.44%
- Short % of float
- 0.80%
Fundamental scorecard
6 of 25 checks passed on BGLC’s reported financials
6of 25 checks passed
- Value 2 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Jun 30, 2026.
Financials — quick view
About BioNexus Gene Lab Corp.
BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers. Its products are used to produce handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms, and covers for various instruments used in manufacturing. The company also involves in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers to detect potential risk of diseases. It markets its products through its website, warehouse, marketing personnel, and suppliers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.
- Sector
- Basic Materials
- Industry
- Specialty Chemicals
- Country
- Malaysia
- Website
- bionexusgenelab.com
News
12 Industrials Stocks Moving In Wednesday's Pre-Market Session
BioNexus Launches BGLC 1Lab Pilot for GeneMatrix Workflows at MRNA Scientific
BioNexus Launches New Corporate Website with Expanded Business and Investor Resources
BioNexus to Build AI Applications for Malaysian Healthcare Under Exclusive CogniAI Licence
RYET to Enter Malaysian Healthcare Through Exclusive Cogni AI License to BioNexus Gene Lab
BioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working Visit
BioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-Development
BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD Platform
BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman
Financial Comparison: Beauty Health (NASDAQ:SKIN) vs. BioNexus Gene Lab (NASDAQ:BGLC)
Your note
Sign in to keep a note on BGLC — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| UBS Group AG | 0.46% | 83,308 | 20.24K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.13% | 23,681 | 5.75K | Sep 29, 2024 |
| Cambridge Investment Research Advisors Inc. | 0.07% | 12,960 | 3.15K | Sep 29, 2024 |
| Scientech Research LLC | 0.06% | 10,385 | 2.52K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.13% | 23,681 | 5.75K | Oct 30, 2024 |
